The Evolving Pathophysiology of Sjögren's Exocrinopathy

Sjögren's disease presents a significant clinical challenge for rheumatologists and internists worldwide. Traditionally, clinicians recognize this autoimmune disorder by persistent xerostomia and keratoconjunctivitis sicca resulting from chronic exocrine destruction. However, current therapeutic interventions remain largely palliative rather than disease-modifying. Recent translational insights into cytokine signaling have identified the Janus kinase and signal transducer and activator of transcription pathway as a central pathogenic driver. Consequently, targeted modulation using ruxolitinib in Sjögren's disease has emerged as a promising avenue to halt progressive glandular injury.

Historically, pathogenic paradigms focused predominantly on aberrant B-cell activation and autoantibody generation. Moreover, infiltrating lymphocytic aggregates drive substantial glandular inflammation and tissue architectural destruction. Pro-inflammatory cytokines such as interferon-gamma and interleukin-6 continuously stimulate local glandular cells through downstream cascades. Therefore, sustained kinase phosphorylation perpetuates a destructive cycle within the submandibular and parotid glands. In addition, persistent inflammation disrupts normal neurosecretory signaling pathways. Thus, blocking these intracellular cascades offers clinicians an innovative mechanism to preserve glandular function. Recent bench-to-bedside inquiries emphasize that interrupting this signaling network can transform our management of autoimmune exocrinopathy.

Evaluating Ruxolitinib in Sjögren's Disease Across Murine Models

To evaluate this therapeutic concept, investigators assessed the oral Janus kinase inhibitor ruxolitinib in distinct preclinical murine cohorts. Specifically, researchers administered either active vehicle or ruxolitinib for two weeks to NOD.B10 and Aec mouse strains. Both animal models spontaneously develop autoimmune sialadenitis mimicking human disease features. However, baseline phenotypic evaluations revealed crucial immunological differences between the two cohorts. For instance, Aec mice exhibited a significantly more robust baseline inflammatory profile than NOD.B10 counterparts. Furthermore, this intense inflammation presented as pronounced lymphocytic infiltration within submandibular salivary glands alongside marked hypergammaglobulinemia.

Consequently, therapeutic responsiveness diverged sharply between these distinct genetic backgrounds. In Aec mice, two weeks of ruxolitinib treatment dramatically lowered circulating plasma immunoglobulin G concentrations. Additionally, therapy significantly decreased plasma concentrations of CXCL13, a critical chemokine governing lymphoid follicle assembly. Most importantly, histology revealed a marked decrease in salivary gland focus score among treated Aec mice. In contrast, NOD.B10 mice exhibited minimal therapeutic response under identical experimental conditions. Therefore, these experimental observations underscore that disease endotypes dictate pharmacological responsiveness in autoimmune salivary disease.

Mechanisms of JAK-STAT Inhibition on Glandular Infiltrates

Detailed cellular profiling provides compelling mechanistic explanations for the selective efficacy seen during therapy. Using high-parameter flow cytometry, investigators examined the intracellular activation states of salivary gland cells. Consequently, they discovered striking elevations of phosphorylated STAT1 across several resident and infiltrating lineages in untreated Aec mice. Phosphorylated STAT1 serves as a major molecular beacon reflecting interferon-driven cellular stress. Furthermore, ruxolitinib treatment significantly reduced phosphorylated STAT1 levels across salivary epithelial cells, infiltrating leukocytes, and stromal fibroblasts.

Importantly, these molecular changes correlated directly with functional organ outcomes. Researchers observed that salivary flow rate correlated inversely with tissue phosphorylated STAT1 expression. Therefore, silencing this kinase pathway directly preserved functional secretory capacity in exocrine tissue. In addition, local focus score severity tracked closely with levels of kinase phosphorylation. By shutting down STAT1 phosphorylation, ruxolitinib effectively dampened local transcriptional programs that recruit destructive lymphocytes. Consequently, the resolution of cellular inflammation restored homeostatic glandular conditions. These findings confirm that interrupting phosphorylated STAT1 halts progressive exocrine tissue dysfunction.

Stromal Reprogramming and Fibroblast-Macrophage Dynamics

Beyond traditional immune cell subsets, stromal fibroblasts actively shape chronic inflammatory microenvironments. Indeed, recent spatial transcriptomics and immunofluorescence profiling revealed profound alterations in glandular architecture following ruxolitinib administration. In untreated diseased glands, activated fibroblasts establish dense networks directly adjacent to pro-inflammatory macrophages. Consequently, this proximity facilitates mutual cross-talk that amplifies local tissue injury and fibrosis. Moreover, salivary fibroblasts display pronounced immune-modulating properties under sustained cytokine exposure. Therefore, resident structural cells actively propagate destructive inflammatory signaling rather than functioning merely as inert scaffolding.

Remarkably, ruxolitinib administration altered these pathological fibroblast-macrophage spatial relationships within the submandibular glands. Through spatial sequencing, researchers demonstrated that kinase inhibition dispersed these tight cellular associations. Furthermore, treatment down-regulated key pro-inflammatory pathways within the fibroblast compartment itself. This stromal reprogramming prevented sustained macrophage recruitment and blunted secondary lymphoid aggregate organization. Additionally, targeting the stromal niche attenuated local chemokine gradients that maintain ectopic germinal centers. Thus, modifying fibroblast immunobiology represents an essential mechanism of action for Janus kinase inhibitors in Sjögren's disease.

Translational Horizons for Clinical Rheumatology Practice

These preclinical breakthroughs offer profound insights for practicing clinicians managing primary Sjögren's disease. Because human patients present with marked clinical and biological heterogeneity, a uniform therapeutic approach often fails in clinical trials. Notably, divergent responses in Aec versus NOD.B10 models directly mirror human phenotypic subsets. Patients exhibiting prominent interferon gene signatures and elevated baseline inflammation will most likely benefit from targeted kinase inhibition. Consequently, molecular stratification could become essential before initiating targeted kinase therapies.

Furthermore, therapeutic strategies must expand beyond conventional lymphocytic targeting. By highlighting the pivotal contribution of glandular fibroblasts, this research establishes stromal cells as viable therapeutic targets. In the clinic, targeting stromal-immune interactions could prevent irreversible gland atrophy and severe xerostomia. While clinicians eagerly await human clinical validation, existing approved Janus kinase inhibitors offer substantial hope. Moreover, future clinical trials should incorporate spatial tissue markers and circulating chemokines such as CXCL13 to monitor therapeutic efficacy. Ultimately, precision medicine will empower clinicians to deliver individualized therapies that arrest autoimmune exocrine destruction.

How does ruxolitinib alter salivary gland histopathology in Sjögren's disease?

In preclinical models, ruxolitinib significantly reduces the glandular focus score and suppresses lymphocytic infiltration in submandibular salivary glands. Furthermore, the therapy disrupts pathological spatial interactions between resident fibroblasts and pro-inflammatory macrophages. By down-regulating phosphorylated STAT1 within epithelial cells, leukocytes, and stromal elements, ruxolitinib decreases local chemokine production. Consequently, this biochemical cascade prevents structural tissue destruction, preserves acinar architecture, and restores glandular secretory function.

Why did ruxolitinib demonstrate efficacy in Aec mice but not in NOD.B10 mice?

The divergent response highlights significant immunological heterogeneity between mouse models of Sjögren's disease. Specifically, Aec mice exhibit a robust inflammatory phenotype characterized by marked lymphocytic infiltration, high phosphorylated STAT1 levels, and elevated systemic CXCL13. Because ruxolitinib specifically inhibits Janus kinase pathways driving this intense inflammatory milieu, it achieved pronounced efficacy in Aec mice. Conversely, NOD.B10 mice feature alternative pathogenic mechanisms that demonstrate limited responsiveness to targeted kinase inhibition.

What role do stromal fibroblasts play in the immunopathogenesis of Sjögren's disease?

Stromal fibroblasts serve as active immunomodulatory drivers within the salivary microenvironment rather than passive architectural cells. When stimulated by pro-inflammatory cytokines, fibroblasts upregulate immune markers, recruit macrophages, and produce key chemokines like CXCL13. Consequently, they establish dense spatial niches that maintain chronic lymphocytic infiltration and ectopic lymphoid structures. Inhibiting Janus kinase signaling represses this pathological fibroblast phenotype, thereby interrupting cellular cross-talk and resolving persistent glandular inflammation.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Adam RJ et al. Ruxolitinib improves outcomes in association with altered fibroblast immunobiology in mouse models of Sjögren's disease. Rheumatology (Oxford). 2026 Nov 10. doi: undefined. PMID: 43007319.


2. Sisto M, Ribatti D, Lisi S. Organ-specific autoimmune disease: Sjögren's syndrome and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Int J Mol Sci. 2020;21(23):9107.


3. Bodewes ILA, et al. Systemic interferon type I and type II signatures in primary Sjögren's syndrome. Ann Rheum Dis. 2018;77(5):776-783.